Clinical trials: Sepsis
Severe Sepsis, Septic Shock
Pharmacogenomic Biomarker Study for Recombinant Human Activated Protein C Treatment in Severe Sepsis
The overall purpose of the study is to determine whether either of the Improved Response Polymorphisms (IRPs) individually predicts a differential DrotAA treatment effect in patients with severe sepsis and high risk of death.
- Trial name
- NCT01486524
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 3,000 people
- Sponsor
- Sirius Genomics Inc.
Pneumonia, Meningitis
Colombia Epidemiologic Surveillance Study
The study will determine the reduction in invasive pneumococcal disease (IPD) after the introduction of a National Immunization Program with PCV-7 in Bogota.
- Conditions
- Pneumonia, Meningitis, Bacteremia, Sepsis
- Trial name
- LEAP II (NCT00428051)
- Testing
- Surveillance
- Where
- 3 sites in Brazil, Colombia and 1 more
- Volunteers
- 32,867 people
- Sponsor
- Pfizer
Staphylococcal Sepsis
Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis
Evaluate the safety, PK and efficacy comparing Pagibaximab Injection to placebo in preventing staphylococcal sepsis in very low birth weight infants.
- Trial name
- NCT00646399
- Testing
- Pagibaximab 50 mg/mL
- Where
- United States
- Volunteers
- 1,579 people, healthy volunteers welcome
- Sponsor
- Biosynexus Incorporated
Severe Sepsis
Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis
Study will evaluate the safety and potential benefit of recombinant human talactoferrin as an addition to the standard care of severe sepsis.
- Trial name
- NCT00630656
- Testing
- Talactoferrin alfa
- Where
- 34 sites in United States, Canada and 3 more
- Volunteers
- 190 people
- Sponsor
- Agennix
Acute Respiratory Distress Syndrome, Acute Lung Injury
Efficacy Study of CytoSorb Hemoperfusion Device on IL-6 Removal in ARDS/ALI Patients With Sepsis
The hypothesis of this study is use of CytoSorb hemoperfusion device as an adjunctive therapy to the standard of care in treating ARDS/ALI patients in the setting of sepsis will result in improved clearance of cytokines when…
- Conditions
- Acute Respiratory Distress Syndrome, Acute Lung Injury, Sepsis
- Trial name
- NCT00559130
- Testing
- CytoSorb Hemoperfusion
- Where
- 6 sites in Germany
- Volunteers
- 100 people
- Sponsor
- MedaSorb Technologies, Inc
Sepsis, Disseminated Intravascular Coagulation
Safety and Efficacy of ART-123 in Subjects With Sepsis and Disseminated Intravascular Coagulation
The purpose of this study is to see if ART-123 (recombinant human soluble thrombomodulin) decreases the number of people who die as a result of Disseminated Intravascular Coagulation (DIC) complication of sepsis.
- Trial name
- NCT00487656
- Testing
- ART-123
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 750 people
- Sponsor
- Artisan Pharma, Inc.
Severe Sepsis
Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)
In this trial, patients with severe sepsis and low protein C levels will receive drotrecogin alfa (activated) at the normal, approved dose and time of administration [24 microgram/kilogram/hour (mcg/kg/hour) for 96 hours] or will…
- Trial name
- NCT00386425
- Testing
- Drotrecogin alfa (activated)
- Where
- 47 sites in United States, Belgium and 7 more
- Volunteers
- 486 people
- Sponsor
- Eli Lilly and Company
Severe Sepsis
Study of Procalcitonin (PCT)-Guided Antibiotic Use in Severe Sepsis Patients Without Obvious Infection
A recent study has demonstrated that in low respiratory infections, a strategy using prescription of antibiotics based on the pro-calcitonin level allows decreasing recourse to antibiotics by 47% without prognostic modification.
- Trial name
- Pro-SEPS (NCT01025180)
- Testing
- Procalcitonin level
- Where
- 9 sites in France
- Volunteers
- 62 people
- Sponsor
- Brahms France
Low Gelsolin, Trauma
Ascending Single Dose Study of Rhu-pGelsolin in Patients With Decreased Gelsolin Levels
This study is designed to assess the pharmacokinetics and safety of an infusion of a single dose of recombinant plasma gelsolin (rhu-pGelsolin) when given to patients admitted to the Intensive Care Unit with documented low levels…
- Conditions
- Low Gelsolin, Trauma, Infection, Burns
- Trial name
- NCT00671307
- Testing
- rhu-pGelsolin
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Critical Biologics Corporation
Bacteriaemia, Catheter Related Bloodstream Infection
Rate of Catheter Colonization and Risk of Bloodstream Infection During Use of Two Different Central Venous Catheters (CVC)
The use of these catheters is associated with infectious complications that are an important iatrogenic source of morbidity and mortality.
- Trial name
- NCT00555282
- Testing
- central venous catheter
- Where
- 2 sites in Czechia
- Volunteers
- 680 people
- Sponsor
- B. Braun Melsungen AG
Sepsis
Follow-up Data of Patients Treated With XIGRIS® in France
The transparency commission wishes that the laboratory Lilly France sets up a follow-up study describing the conditions of use of Xigris® in France.
- Trial name
- NCT00803231
- Where
- France
- Volunteers
- 1,004 people
- Sponsor
- Eli Lilly and Company
Sepsis, Septic Shock
Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock
The study will evaluate the vasopressor requirement, hemodynamic response and measures of tissue perfusion in patients with septic shock receiving an infusion of drotrecogin alfa (activated) compared to patients not receiving…
- Trial name
- NCT00279214
- Testing
- drotrecogin alfa (activated)
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- Eli Lilly and Company
Bacteremia, Staphylococcal Infection
MicroPhage S. Aureus / MSSA / MRSA Blood Culture Beta Trial
In-vitro identification of S. aureus, methicillin-sensitive S. aureus (MSSA), and methicillin-resistant S. aureus (MRSA) from positive blood cultures by MicroPhage's bacteriophage-based diagnostic platform.
- Conditions
- Bacteremia, Staphylococcal Infection, Sepsis, Infection
- Trial name
- NCT00814151
- Testing
- MicroPhage S. aureus / MSSA / MRSA Blood Culture Test (prototype)
- Where
- 3 sites in United States
- Volunteers
- 712 people
- Sponsor
- MicroPhage, Inc.
Staphylococcal Sepsis
Safety and Pharmacokinetics Study in Adults for the Prevention of S. Epidermidis Infection in Low Birth Weight Infants
The purpose of this Phase 1 study is to evaluate the safety and pharmacokinetics of BSYX-A110 in a small number of healthy adult volunteers.
- Trial name
- NCT00636285
- Testing
- BSYX-A110
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Biosynexus Incorporated
Pneumonia, Bacterial
Study Evaluating Streptococcus Pneumoniae Serotype Carriage Rate for Nasopharyngeal Carriage in Filipino Children
Evaluation of the carriage rate of Streptococcus pneumoniae in the nasopharynx of healthy children and the carriage rate and distribution of Streptococcus pneumoniae serotypes
- Trial name
- NCT00724828
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Staphylococcal Sepsis
Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW Neonates of BSYX-A110
The purpose of this study is to evaluate the safety (including tolerability), pharmacokinetics, pharmacodynamics and clinical activity of BSYX-A110 administered in a 3-dose regimen on Study Days 0, 7, and 14.
- Trial name
- N003 (NCT00631800)
- Testing
- Pagibaximab (formerly BSYX-A110)
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Biosynexus Incorporated
Neonatal Staphylococcal Sepsis
Safety and Pharmacokinetics Study in VLBW Neonates With BSYX-A110
"Phase I/II, Randomized, Double Blind, Placebo Controlled, Dose Escalating, Safety and Pharmacokinetics Study in Very Low Birth Weight Neonates of Four Doses of BSYX-A110 for the Prevention of S.
- Trial name
- N002 (NCT00631878)
- Testing
- Pagibaximab (formerly BSYX-A110)
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Biosynexus Incorporated
Sepsis, Hematologic Neoplasms
A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation
The purpose is to determine how Drotrecogin Alfa (activated) will affect patients with blood cancers who develop severe sepsis within 60 days of starting chemotherapy in preparation for bone marrow transplant (BMT).
- Conditions
- Sepsis, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Infection
- Trial name
- NCT00067730
- Testing
- Drotrecogin Alfa (activated)
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Eli Lilly and Company
Sepsis
The Study of Drotrecogin Alfa (Activated) in Adult Patients With Severe Sepsis at a Low Risk of Death
Adult Patients with Severe Sepsis
- Trial name
- NCT00568737
- Testing
- Drotrecogin alfa (activated)
- Where
- 70 sites in Argentina, Australia and 10 more
- Volunteers
- 2,640 people
- Sponsor
- Eli Lilly and Company
Severe Sepsis
An Open Label Study of Severe Sepsis in Adults
This trial is to obtain safety data in adult patients with severe sepsis and two sepsis-induced organ infections who receive an infusion of drotrecogin alfa (activated).
- Trial name
- NCT00568893
- Testing
- drotrecogin alfa (activated)
- Where
- 18 sites in Belgium
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company